drug · small molecule
hexaminolevulinate hydrochloride
Marketedupdated 3mo agoby Asieris Pharmaceuticals (USA) Inc🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for carcinoma and 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying hexaminolevulinate hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 19, 2036
~10.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Jan 4, 2038method-of-use (U-2250)US 11235168
- Dec 19, 2036method-of-use (U-2250)US 10556010
- Dec 19, 2036method-of-use (U-2250)US 11311620
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that